By Fineline Cube 
Astellas Pharma Inc. (TYO: 4503) released its consolidated six‑month results for fiscal year 2025 (1 Apr 2025 – 30 Sep 2025). The Japanese‑based pharmaceutical group delivered JPY 1,030.1 bn (≈ USD 6.69 bn) in net revenue, up 10.1 % YoY, and Core Operating Profit of JPY 282.6 bn (≈ USD 1.84 bn), a 54.4 % YoY increase.
Revenue Breakdown by Region (H1 FY2025)
| Region | Revenue (JPY bn) | YoY Growth |
|---|---|---|
| Japan | 142.9 | +7.0 % |
| United States | 457.1 | +9.0 % |
| Established Markets* (Europe, Canada, etc.) | 264.9 | +10.4 % |
| China (Mainland & Hong Kong) | 49.7 | +32.0 % |
| International Markets† (LatAm, MEA, SEA, South Asia, Russia, South Korea, Taiwan, Australia, etc.) | 111.5 | +11.5 % |
*Europe, Canada and other mature markets.
†All other territories not listed above.
Strategic Brand Performance
- Strategic‑Brand revenue: > JPY 220 bn, +43 % YoY.
- Padcev (enfortumab vedotin) – JPY 102.5 bn (+35.9 %)
- Izervay (avacincaptad pegol) – JPY 34.1 bn (+21.4 %)
- Veozah/Veoza (fezolinetant) – JPY 22.9 bn (+54.7 %)
- Vyloy (zolbetuximab) – JPY 26.6 bn (+>100 %)
- Xospata (gilteritinib) – JPY 34.4 bn (stable)
- Xtandi (enzalutamide) – JPY 477.0 bn (+5.6 %)
Full‑Year FY2025 Guidance Update
| Metric | Prior Guidance | Revised Guidance |
|---|---|---|
| Net Sales | JPY 1,930.0 bn | JPY 2,030.0 bn |
| Core Operating Profit | JPY 160.0 bn | JPY 240.0 bn |
Management attributed the upward revision to strong U.S. performance, accelerated growth in China, and double‑digit gains from the newly launched strategic brands.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties, including future sales, profitability, regulatory approvals and market conditions. Actual results may differ materially from those expressed herein.-Fineline Info & Tech